TP53 and cancer: To investigate, a regression was fit to predict activity (log IC50) for each drug, from cancer type and each cancer gene mutation status (via the CFE classification, see Methods), and additionally introducing TP53 status (either via TP53 mutation (“CFE”), or via TP53 phenocopy score) as an interaction term in the regression.